Sentynl Theraps Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SENTYNL THERAPS INC
SENTYNL THERAPS INC has four approved drugs.
There are two US patents protecting SENTYNL THERAPS INC drugs.
There are fifteen patent family members on SENTYNL THERAPS INC drugs in thirteen countries and twelve supplementary protection certificates in four countries.
Summary for Sentynl Theraps Inc
| International Patents: | 15 |
| US Patents: | 2 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Sentynl Theraps Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sentynl Theraps Inc | ZYCUBO | copper histidinate | POWDER;SUBCUTANEOUS | 211241-001 | Jan 12, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Sentynl Theraps Inc | ABSTRAL | fentanyl citrate | TABLET;SUBLINGUAL | 022510-005 | Jan 7, 2011 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Sentynl Theraps Inc | ZOKINVY | lonafarnib | CAPSULE;ORAL | 213969-001 | Nov 20, 2020 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sentynl Theraps Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sentynl Theraps Inc | ABSTRAL | fentanyl citrate | TABLET;SUBLINGUAL | 022510-004 | Jan 7, 2011 | 6,759,059 | ⤷ Start Trial |
| Sentynl Theraps Inc | ABSTRAL | fentanyl citrate | TABLET;SUBLINGUAL | 022510-003 | Jan 7, 2011 | 6,761,910 | ⤷ Start Trial |
| Sentynl Theraps Inc | ABSTRAL | fentanyl citrate | TABLET;SUBLINGUAL | 022510-001 | Jan 7, 2011 | 6,761,910 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SENTYNL THERAPS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Sublingual Tablets | 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.6 mg and 0.8 mg | ➤ Subscribe | 2014-06-19 |
International Patents for Sentynl Theraps Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 4436800 | ⤷ Start Trial |
| Canada | 2501464 | ⤷ Start Trial |
| Poland | 1664317 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sentynl Theraps Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0836511 | 122006000022 | Germany | ⤷ Start Trial | PRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126 |
| 0836511 | SPC/GB06/022 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124 |
| 0901368 | C300523 | Netherlands | ⤷ Start Trial | PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
